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Abstract The human ether-a-go-go-related gene (herg) encodes
a K+ current (IHERG) which plays a fundamental role in heart
excitability and in neurons by contributing to action potential
repolarization and to spike-frequency adaptation, respectively. In
this paper we show that IHERG, recorded in neuroblastoma cells
and guinea-pig ventricular myocytes, was reversibly inhibited by
the KATP channel blocker glibenclamide (IC50 = 74 WM). The
voltage and use dependence of glibenclamide blockade were also
evaluated. Another sulfonylurea, glimepiride, had less effective
results in blocking IHERG. The findings of this study are relevant
to the interpretation of glibenclamide effects on cellular
electrophysiology and suggest that oral antidiabetic therapy
with sulfonylureas may contribute to iatrogenic QT prolongation
and related arrhythmias.
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1. Introduction
Sulfonylurea compounds, such as glibenclamide, are block-
ers of the K current sensitive to intracellular ATP (IKATP)
widely used in the treatment of non-insulin-dependent diabe-
tes mellitus. Long-QT syndrome, secondary to antidiabetic
therapy with glibenclamide, has been recently reported [1].
This implies an action of glibenclamide on repolarizing cur-
rents.
Based on the assumption of a selective e¡ect of glibencla-
mide on cardiac IKATP (IC50 of 5^10 WM), this drug has been
extensively used as a pharmacological tool in investigating the
pathophysiology of ischemia [2]. However, glibenclamide also
blocks the cardiac cAMP-activated chloride conductance, the
cystic ¢brosis conductance regulator chloride (CFTR) cur-
rents (IC50 = 30 WM) [3^5] and a Ca2- and ATP-independent
K current in a human neuroblastoma cell line [6]. Interfer-
ence of glibenclamide with delayed recti¢er currents, unde-
tected so far, would be particularly relevant to the use of
glibenclamide as a research tool.
The present work investigates the e¡ects of glibenclamide
on neuronal and cardiac K currents, with a focus on the
channel (IHERG or IKr) encoded by the human ether-a-go-go-
related gene (herg) [7^9]. The functional role of IHERG (IKr) in
the control of repolarization in the heart and in spike-fre-
quency accommodation in the nervous system [10,11] moti-
vates the interest in its modulation by glibenclamide. Neuro-
blastoma cells intrinsically expressing IHERG [12^14] were
ideally suited to test the dose dependence, mode of blockade
and e¡ects on resting potential (VREST). Experiments on car-
diac myocytes allowed a comparison of glibenclamide e¡ect
on the rapid (IKr) and slow components (IKs, encoded by
minK and KvLQT1 genes) [15,16] of the delayed recti¢er cur-
rent. The impact of glibenclamide-induced channel blockade
on repolarization was also tested in this cell type.
2. Materials and methods
2.1. Cell culture and isolation
Experiments were carried out on cultured neuroblastoma cells and
on freshly dissociated guinea-pig ventricular myocytes. The rat dorsal
root ganglia (DRG)Umurine neuroblastoma hybrid cell line F11, and
the human neuroblastoma SH-SY5Y were cultured in Dulbecco’s
modi¢ed Eagle’s medium (DMEM), containing 4.5 g/l of glucose
and 10% fetal calf serum (FCS). Cells were incubated at 37‡C in a
humidi¢ed atmosphere with 5% CO2 (10% for SH-SY5Y). Guinea-pig
ventricular myocytes were freshly dissociated according to a previ-
ously described procedure [17] and preserved in a low Ca2 medium
at 4‡C until use.
2.2. Patch clamp recordings
Membrane currents and voltage were recorded (Axopatch 200A,
Axon, Foster City, CA, USA) in the whole-cell con¢guration by using
pipettes with tip resistance in the range of 2^4 M6. Series resistance
and capacitance were compensated to about 80^90% of their initial
value. The pipette junction potential was not corrected. Cells were
perfused through a microperfusion system allowing for solution
changes to occur within 1 s approximately. While neuronal currents
were studied at room temperature, reliable measurements of cardiac
ones required temperatures in the physiological range (36 þ 0.5‡C).
2.3. Protocols
In neuroblastoma cells IHERG were elicited at [K]o = 40 mM from a
holding potential (VH) of 0 mV as tail currents tested at 3120 mV, as
previously reported [11^14]. In cardiac cells delayed recti¢er K cur-
rents were activated by step depolarizations from VH of 340 mV. The
amplitude of IKr during the depolarizing step re£ects the interplay
between channel activation and inactivation; thus, drug e¡ects were
generally tested on tail currents recorded upon returning to negative
potentials, which should be a¡ected by channel activation only [18].
Potential interference by other currents was minimized by examining
outward tail currents in ventricular myocytes (test potential 340 mV,
[K]o = 4 mM). In the cardiac cells contamination by Ca2 currents
was prevented by adding nisoldipine (0.2 WM) to all solutions. The
rapid (IKr) and slow (IKs) components of the delayed recti¢er current
were dissected by means of both voltage protocols and the use of
channel blockers E-4031 (speci¢c for IKr) and chromanol 293B (spe-
ci¢c for IKs) [19]. In some cases, glibenclamide e¡ects were expressed
by comparing glibenclamide-sensitive current (Iglib = I in control mi-
nus I in glibenclamide) to currents sensitive to E-4031 (IEÿ4031) and
chromanol (I293B), that can be safely assumed to re£ect IKr and IKs,
respectively. In both neural and cardiac cells, activation curves were
constructed by measuring the amplitude of tail currents following long
(steady-state) pulses at various potentials. Average normalized tail
amplitudes were best ¢tted with Boltzmann functions and the relevant
parameters were estimated.
2.4. Solutions
For neuronal cells the standard extracellular solution contained
(mM): NaCl 130, KCl 5, CaCl2 2, MgCl2 2, HEPES-NaOH 10, D-
glucose 5, pH 7.4. When necessary, the NaCl was replaced by KCl to
[K]o = 40 mM. The standard pipette solution at [Ca2]i = 1037 M
(pCa 7) contained (mM): K-aspartate 130, NaCl 10, MgCl2 2, CaCl2
1.3, EGTA-KOH 10, HEPES-KOH 10, ATP (Mg2 salt) 1, pH 7.3.
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For cardiac cells the standard extracellular solution contained (mM):
NaCl 154, KCl 4, CaCl2 2, MgCl2 1, HEPES-NaOH 5, D-glucose 5.5,
pH 7.35. The pipette solution contained (mM) K-aspartate 110, KCl
23, EGTA-KOH 1, CaCl2 0.4 (pCa 7), MgCl2 3, HEPES-KOH 5,
GTP (Na salt) 0.4, ATP (Na salt) 5, creatine phosphate 5, pH
7.3. In evaluating IKr, IKs contamination was minimized by adding
the speci¢c blocker chromanol 293B (10 WM) [19] to all solutions. In
evaluating IKs, IKr contamination was removed by adding 5 WM E-
4031, the speci¢c blocker of IKr.
Glibenclamide (RBI), glimepiride (a kind gift from Dr. P. Marche-
tti) and chromanol 293B were dissolved in DMSO, nisoldipine in
ethanol and E-4031 and WAY 123,398 (Wyeth-Ayerst Research,
Princeton, NJ, USA) in water. Stock solutions of each substance
were diluted in extracellular solution to the desired concentration.
Ethanol and DMSO, present at ¢nal concentrations 90.1%, were
included in control as well as test solutions. Nisoldipine, E-4031
and chromanol 293B were generous gifts from Bayer Pharmaceuticals,
Sano¢ Recherche and Roche Pharmaceuticals, respectively.
2.5. Statistical analysis
The Student’s t-test was used to compare di¡erences between sam-
ple means. Best ¢ts of experimental points to Hill and Boltzmann
functions were obtained by non-linear, least-square ¢tting routines
(Microcal Origin). Di¡erences between ¢tted curves were tested by
considering the overlap between their 0.05 con¢dence intervals. Sig-
ni¢cance was de¢ned by P6 0.05. Results are presented as mean þ
S.E.M.
3. Results
3.1. Experiments in neuroblastoma cells
3.1.1. Glibenclamide blockade of IHERG and its dose-depend-
ence. The e¡ect of 1 min glibenclamide superfusion on IHERG
in F11 cells is shown in Fig. 1A. Changes were fully reversible
within 2 min of washout and were reproduced by a second
application of the drug. Similar results were obtained in the
human neuroblastoma SH-SY5Y (not shown).
The e¡ect of glibenclamide (100 WM) on VREST [13,14]
which in neuroblastoma cells is governed by IHERG [12], was
tested under current-clamp conditions (I = 0). A representative
record from such an experiment is shown in Fig. 1B. The
average depolarization induced by glibenclamide (8 þ 2.2
mV, n = 5; P6 0.05) was comparable to that caused in the
same cell type by other HERG channel blockers [13].
The dose-response relationship of glibenclamide e¡ect on
IHERG in F11 cells is shown in Fig. 1C. Data obtained in
SH-SY5Y did not di¡er signi¢cantly (not shown). Fractional
current inhibition at each concentration was expressed as
unity minus the ratio between current amplitudes measured
under test and control conditions. Fractional inhibition values
were best ¢tted by the Hill function (1+(IC50/[glib])p)31, where
[glib] is glibenclamide concentration, IC50 is [glib] exerting
50% inhibition, and ‘p’ is the Hill number. The ¢tting proce-
dure estimated a glibenclamide IC50 of 74.8 þ 7 WM with
p = 0.82 þ 0.05. Glimepiride, another sulfonylurea drug, was
also tested for comparison. The results are reported in Fig.
1C for concentrations of 10, 50, 100 and 500 WM. Glimepiride
appeared to be about ten times less e¡ective than glibencla-
mide in blocking IHERG. We were not able to test higher gli-
mepiride concentrations because it became insoluble and pre-
cipitated in the perfusion tubes.
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Fig. 1. Glibenclamide blockade of IHERG in neuronal cells. A: Reversibility of block. IHERG was elicited by stepping to 3120 mV from a hold-
ing potential of 0 mV (see below); glibenclamide (100 WM) was applied twice (1st and 2nd glib) for 60-s periods followed by 2 min washout
(1st and 2nd washout). B: Time course of changes in resting membrane potential (VREST) of an F11 cell during 90 s superfusion with glibencla-
mide (marked by the bars). C: Fractional inhibition of IHERG tail currents by glibenclamide concentrations of (WM): 1 (n = 5), 5 (n = 4),
10 (n = 5), 20 (n = 7), 50 (n = 11), 100 (n = 6), 200 (n = 2), 500 (n = 2). The solid line represents best ¢t of data points with Hill function (see text
for parameters). Data obtained with glimepiride concentrations of (WM) 10 (n = 3), 50 (n = 5), 100 (n = 5), 500 (n = 3) are reported (E) in the
same diagram for comparison.
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3.1.2. Voltage and use dependence of IHERG blockade. In
order to investigate the mode of glibenclamide action we
tested if (i) the voltage dependence of IHERG activation and
inactivation were modi¢ed by the drug; and (ii) if, similarly to
other organic IHERG blockers [20], glibenclamide e¡ect was
use-dependent.
Fig. 2A shows average activation curves obtained from
4 cells under control conditions and during superfusion with
glibenclamide; activation parameters were estimated from
Boltzmann ¢ts of average experimental points. The membrane
potential required for 50% current activation (V0:5) and the
Boltzmann slope (k) were 335 mV and 6.6 mV, respectively,
in control and 338.7 and 7.8 mV, respectively, during expo-
sure to glibenclamide. However, these di¡erences appeared
not to be signi¢cant. The properties of the other voltage-de-
pendent gate, namely inactivation [13], were tested in 3 cells.
Inactivation parameters V0:5 and k were, respectively, 338.6
and 21.9 mV in control and 339.6 and 27.2 mV during gli-
benclamide delivery. These di¡erences were again not signi¢-
cant.
Use dependence of the glibenclamide e¡ect on IHERG was
studied with the protocol shown in Fig. 2B. Superimposition
of tail currents from individual pulses (Fig. 2C) shows that the
glibenclamide e¡ect, present at the ¢rst pulse, was unchanged
in the following ones. This is at variance with the progressive
development of blockade during subsequent pulses of the
train, induced by the use-dependent IHERG blocker WAY
123,398 (Fig. 2C, inset) [21]. The reduction of the outward
current at +10 mV, which can be observed during glibencla-
mide application, is due to blockade of a delayed recti¢er
K current by the drug [6]. This e¡ect cannot be seen in
Fig. 1A, since the delayed recti¢er current is inactivated
(VH = 0 mV).
3.2. Experiments on cardiac ventricular myocytes
Since ventricular myocytes express two types of delayed
recti¢er current (IKr and IKs), in these cells glibenclamide ef-
fects were best described by comparison with those of selective
blockers of each component (E-4031 and chromanol 293B).
3.2.1. Comparison of the e¡ects of glibenclamide and E-4031
on IKr (HERG). In evaluating IKr, relatively short depola-
rizing steps were delivered every 4 s within a range of poten-
tials at which IKs activation was negligible [22]; the e¡ect of
100 WM glibenclamide was compared with that of a saturating
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Fig. 2. Voltage and use dependence of glibenclamide blockade of IHERG in F11 neuroblastoma cells. A: Steady-state IHERG activation curve in
control (E) and during 100 WM glibenclamide (a). For activation, tail current amplitudes were measured at 3120 mV after long conditioning
steps in the range 310 to 360 mV (see inset). Dotted lines are Boltzmann ¢ts of average experimental points (n = 4). For inactivation, from a
holding potential of 0 mV steps were applied in the range +20 to 3120 mV. Tail current amplitudes (shown in the left inset) were divided for
the driving force to determine HERG conductance. The mean values obtained (n = 3) are ¢tted with Boltzmann curves (dotted lines). Scalers in
left and right insets represent 50 ms and 300 pA. B: Protocol used to investigate the use dependence of IHERG blockade; an activating step
(+10 mV, 330 ms) was followed by a test pulse (3120 mV, 270 ms); this protocol was applied in runs of 11 episodes at a cycle length of 2 s;
C: Superimposed IHERG tails recorded during individual episodes (from 1 to 11) in control (con) and during 100 WM glibenclamide (glib). The
di¡erence in the outward current at +10 mV is due to partial block of a K delayed recti¢er current by glibenclamide (see text). The inset
shows the same use-dependence protocol applied during steady-state superfusion with 1 WM WAY 123,398.
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concentration (5 WM) of the speci¢c IKr blocker E-4031 [22].
A representative result of this experiment is shown in the
upper panels of Fig. 3. Glibenclamide, 100 WM, reduced IKr
tail amplitude from 13.75 þ 2.44 pA to 5.28 þ 0.981 pA
(361.6 þ 1.4%; n = 5; P6 0.05). After washout, the current
returned to 12.06 þ 1.36 pA (N.S. vs. control) (Fig. 3A). The
amplitude of IKr tail currents was reduced by E-4031 from
16.89 þ 2.93 pA to 1.64 þ 0.91 pA (386.8 þ 6.5%; n = 6;
P6 0.05). As previously described [23], reversal of the E-
4031 e¡ect upon washout was slow and incomplete and could
be observed in 3 out of 6 cells (10.97 þ 3.6 pA) (not shown).
A comparison between the voltage dependence of IKr and of
the current sensitive to glibenclamide was performed by ob-
taining activation curves for Iglib (n = 4) and IEÿ4031 (n = 5). As
tested by taking into account the 0.05 con¢dence limits of the
¢tting functions, the normalized activation curves of Iglib and
IEÿ4031 did not di¡er signi¢cantly. For Iglib and IEÿ4031 V0:5
values were 13.6 and 12.1 mV, respectively; Boltzmann slopes
were 10.4 and 8.3 mV. The maximum current densities, as
estimated from ¢ts of raw data, were 0.409 pA/pF for
IEÿ4031 and 0.339 pA/pF for Iglib (not shown).
3.2.2. Comparison of the e¡ects of glibenclamide and chro-
manol 293B on IKs. With the purpose of evaluating the spe-
ci¢city of glibenclamide e¡ects for either component of the
delayed recti¢er current, we also tested drug e¡ects on IKs.
Such e¡ects were compared to those of the speci¢c IKs blocker
chromanol 293B (10 WM) [19]. The results of this experiment
are exempli¢ed in the bottom panels of Fig. 3. Relatively long
(3-s) depolarizing steps were used to activate IKs. The e¡ect of
glibenclamide was expressed relative to those of chromanol
293B, i.e. by comparing Iglib to chromanol-sensitive current
(I293B). Densities of I293B and Iglib tail currents were
1.27 þ 0.36 pA/pF and 0.41 þ 0.14 pA/pF (n = 5; P6 0.05),
respectively. Thus, on average, Iglib was 30.85 þ 2.72% of
I293B. The e¡ects of both glibenclamide and chromanol 293B
were largely reversible upon washout (Fig. 3B, inset).
3.2.3. E¡ect of glibenclamide on ventricular action potential
duration. In order to investigate the functional signi¢cance
of glibenclamide e¡ects on delayed recti¢er currents, we tested
the e¡ect of this drug on action potentials recorded under I-
clamp conditions (I = 0) during stimulation at a cycle length of
1 s. Action potential duration (APD) was measured at 90% of
repolarization. An example of glibenclamide e¡ect on APD is
shown in panel A of Fig. 4. Superfusion with glibenclamide,
100 WM, reversibly prolonged APD by 9.4 þ 1% (163.9 þ 10.2
ms vs. 150.5 þ 9.9 ms; n = 14; P6 0.05). Even if glibenclamide
blockade of IKs was small, as compared to that of IKr, both
e¡ects might contribute to APD prolongation, depending on
the proportion of delayed recti¢er current accounted for by
each component. To address this issue, we tested the extent of
APD prolongation resulting from the speci¢c inhibition of IKs
by 10 WM chromanol 293B (Fig. 4B) and of IKr by 5 WM E-
4031 (Fig. 4C). APD was prolonged by E-4031 from
148.3 þ 9.9 ms to 184.6 þ 11.6 ms (24.8 þ 3.3%; n = 14;
P6 0.05) and by chromanol 293B from 152.5 þ 12.1 ms to
160.35 þ 12.5 ms (5.3 þ 1.6%; n = 9; P6 0.05). Thus, under
the present experimental conditions, the e¡ect of glibencla-
mide on APD may largely result from IKr (IHERG) inhibition.
4. Discussion
The present work shows that glibenclamide blocks neural
and cardiac delayed recti¢er K currents and prolongs cardiac
repolarization. Although the drug also partly inhibited the
slow component of the cardiac delayed recti¢er current
(IKs), its e¡ects on the HERG type channel (IKr, IHERG)
were more prominent and likely to account for most of the
APD prolongation.
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Fig. 3. E¡ects of 100 WM glibenclamide on IKr and IKs in cardiac ventricular myocytes. Current traces in control and during drug superfusion
(*) are compared in each of the ¢rst two panels; in the third panel control and test traces are subtracted to yield drug-sensitive currents (IE4031,
Iglib and I293B). The insets show plots of tail current amplitude vs. time measured throughout the experiment; the time of drug superfusion is
marked by bars (glib 100 WM, E4031 5 WM; chromanol 293B 10 WM). A: IKr (HERG) was activated by 250-ms steps to 0 mV from a holding
potential of 340 mV (interval 4 s) in the presence of nisoldipine and chromanol 293B. B: IKs was activated by 3-s steps to +30 mV from a
holding potential of 340 mV (interval 10 s) in the presence of nisoldipine and E-4031.
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4.1. Dose dependence
Glibenclamide inhibited IHERG in neuroblastoma cells with
a threshold concentration of 10 WM and an IC50 of 75 WM
(Fig. 1). The Hill coe⁄cient suggests a 1:1 stoichiometry for
the drug-channel interaction. Glimepiride seemed to be less
e¡ective in blocking IHERG, requiring a threshold concentra-
tion of 50 WM. The extent of inhibition of cardiac IKr by 100
WM glibenclamide (61%) was consistent with the dose depend-
ence measured in neuroblastoma cells (60% at 100 WM). Gli-
benclamide concentrations inhibiting IHERG, IKr and IKs were
higher than those active on IKATP in pancreatic L-cells (in the
nM range) [24], but closer to those required to inhibit cardiac
IKATP (1^100 WM) [25^27].
4.2. Mode of IHERG (IKr ) blockade
Failure to a¡ect the voltage dependence of activation and
the lack of use dependence of blockade shows that glibencla-
mide action on IHERG (IKr) was not in£uenced by the gating
state. This, and the fast development of e¡ects, suggest that
glibenclamide may bind to a channel domain exposed to the
extracellular environment. This is at variance with what was
reported for the slowly developing action of glibenclamide on
cAMP-activated Cl-currents [4]. The mode and dose depend-
ence of glibenclamide action were remarkably similar between
neural and cardiac HERG-type currents, thus suggesting com-
mon pharmacological properties between the channel ex-
pressed in the two tissues.
Although to a lesser extent, IKs was also inhibited by gli-
benclamide. It has been recently proposed that a subunit of
the IKs channel (minK) may also contribute to functional ex-
pression of IKr [28]. On the other hand, drug e¡ects on de-
layed recti¢er current and IKATP appear to be closely coupled
in smooth muscle [29]. Thus, the low selectivity of the gliben-
clamide e¡ect might re£ect the presence of speci¢c ‘receptors’
for this drug on all such channels. Indeed, the existence of
sulfonylurea receptors (SUR1, SUR2) with very di¡erent af-
¢nities for glibenclamide [30] which are crucial in the forma-
tion (with the K channel Kir 6.2) of the pancreatic, neural
and muscle ATP-sensitive K channels is well documented .
This ¢nding could suggest that the HERG channels could also
be linked to these receptors. Moreover, our data, showing that
both IKr and IKs (to a much lesser extent) are a¡ected by
glibenclamide, could be explained also in another way: both
these channels have been shown to complex with minK pro-
teins [28] and putatively either minK and/or SUR could form
heteromultimer functional complexes. However, while this re-
mains a matter of speculation, it is di⁄cult to rule out that the
widespread channel blocking e¡ects of glibenclamide may re-
sult from some non-speci¢c property of the molecule.
4.3. Relevance and implications
Glibenclamide concentrations in the 10^100-WM range are
often used to test the role of IKATP in cardiac cellular electro-
physiology both under normal [25] and ischemic conditions
[27] (for review see [31] and [32]). Blockade of cardiac delayed
recti¢er currents, described in the present study, might mimick
the e¡ects expected from IKATP blockade, thus potentially
confusing the interpretation of results.
The hypoglycemic action of glibenclamide, i.e. blockade of
IKATP in pancreatic L-cells, is reported to occur at concentra-
tions in the nanomolar range [24]. Thus, although iatrogenic
long-QT syndrome during glibenclamide therapy has been re-
ported [1], it seems unlikely that glibenclamide alone may be a
widespread cause of clinical proarrhythmia. Nonetheless, it is
di⁄cult to rule out that preexisting primary or iatrogenic
long-QT syndromes may be unmasked or accentuated by
the drug. A similar phenomenon has been described for var-
ious agents (e.g. antiarrhythmic drugs, antihistamines, macro-
lids, antiserotoninergics, antipsychotics, etc.) [33^35] whose
e¡ects on cardiac delayed recti¢er currents caused serious ar-
rhythmias when drugs were administered either in association
or to abnormally sensitive individuals. In this respect, the use
of glimepiride, which was also reported to have less cardio-
vascular side e¡ects in vivo [36], should be taken into account.
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